Page 67 - Libro Memoria Cien Inglés
P. 67
PI: Dr. Stephan Moratti, Basic Episodes: Randomized, Double-
Pasuchology I Professor. Blind, Placebo-Controlled Clinical
• PURPOSE “Placebo-controlled Trial" (Exp/n. SAM18PI02/2019). Dr.
trial in subjects at ultra-high Risk Celso Arango López. Child and
for Psychosis with Omega-3 fatty Adolescent Psychiatry Service,
acids in Europe”. PI: Dr. Covadonga Department of Psychiatry. Gregorio
Martínez Díaz-Caneja. Marañón University General
Hospital.
• "NAC II": "Combination of N-Acetyl
Cysteine (NAC) Treatment and • “Study of the
Cognitive Training to Promote Ethiophysiopathological
Changes in Behavioral and Neural Mechanisms Involved in the
Activation Patterns Underlying Progressive Loss of Brain
Cognitive Deficit in Adolescent Gray Matter in Children and
Psychosis" (Exp/n. FAK182018). Dr. Adolescents with a First Psychotic
Marta Rapado Castro. Child and Episode, Adolescents at Risk and
Adolescent Psychiatry Service, Healthy Controls by the Alonso
Gregorio Marañón University Family Foundation” (Exp/nº
General Hospital, Faculty of FIBHGM_CCA004-2018). PI: Dra.
Medicine, Complutense University, Marta Rapado Castro. Child and
CIBERSAM Adolescent Psychiatry Service,
Gregorio Marañón General
• "Effect of 48-Week University Hospital, Faculty of
N-Acetylcysteine Treatment Medicine, Complutense University,
on Gray Substance Loss and CIBERSAM.
Oxidative Metabolism in Patients
with Early-Onset First Psychotic • “Observational study in young
people with high-risk mental
